Regulation on Products Derived from Human Tissues and Cells (Official Gazette 04.09.2025, No. 33007): A Hard-Edged Compliance Guide for Clinics, Biobanks, and Manufacturing Facilities

Meta title: Human Tissue and Cell Regulation 2026 – Who Is Affected and What Needs to Be Done?
Slug: human-tissue-cell-regulation-2026-compliance-guide
Meta description: The new Regulation on Products Derived from Human Tissues and Cells and Related Centers, effective January 1, 2026. Coverage, license types, quality/traceability, biobank obligations, prohibitions, and sanctions. A step-by-step compliance roadmap for hospitals, biobanks, and ATMP manufacturers.

Straight talk: This is not a “nice overview.” It’s a direct to-do list. The Regulation imposes heavy data retention, traceability, and quality obligations. It takes effect on January 1, 2026. Existing facilities have a one-year transition window. Failure to comply can result in suspension or cancellation of licenses and even closure.

How this article is structured

The section headings are based on actual Google queries. Each section answers one question in depth. At the end, you’ll find FAQ schema and a CTA.

What is the purpose of this new Regulation? Who does it cover and who is excluded?

Purpose: To regulate fair access, quality, and safety standards for human tissue/cell–derived products and to define licensing, infrastructure, staffing, and oversight for centers active in this field.

Scope (summary):

• The entire chain: procurement, testing, processing, preservation, storage, distribution, disposal, transport, and clinical application.

• Imports/exports, monitoring systems, and experimental or clinical trials.

• Biobanking: collection, storage, processing, and sharing of human biological materials and related data.

Exclusions:

• Licensing of bone marrow transplant centers (the transplant act itself is covered).

• Blood banking and plasma fractionation.

• Assisted reproductive (IVF/ART) centers.

• Organ/composite tissue transplants.

• Non-human (animal, plant, synthetic) sources.

• Human tissues/cells collected solely for scientific research, not clinical use.

• Medical devices regulated under separate legislation.

Effective date: January 1, 2026.
Transition: Existing centers must comply within 1 year.
Repealed: 2005 Cord Blood Banking Regulation and the 2010 Tissue/Cell Quality and Safety Regulation.

Who are the competent authorities?

• General Directorate of Health Services (SHGM)

  • Authorizes procurement sources and clinical application centers.

• Turkish Medicines and Medical Devices Agency (TİTCK)

  • Plans, pre-approves, licenses, and inspects tissue/cell centers and biobanks.

• TÜSEB

  • Oversees national automation systems for procurement/distribution and sets procedural rules.

Additionally:

• Tissue and Cell Coordination Commission: strategic, chaired by the deputy minister.

• Scientific advisory committees: technical opinions.

What types of centers can be licensed?

1. Tissue and Cell Procurement Centers

   • Handle autologous/allogeneic procurement.

   • Must ensure donor consent, medical suitability, and records (30 years minimum).

2. Tissue and Cell Centers

   • Licensed for procurement, processing/production, or storage/distribution (one or multiple).

   • Processing/production centers: must comply with GMP/GTP/GLP; final release criteria; expiry dates.

   • Storage/distribution centers: responsible for safety during storage, import/export, and pre-clinical checks.

3. Clinical Application Centers

   • Apply licensed tissues/cells and Advanced Therapy Medicinal Products (ATMPs).

   • Must report adverse events/effects back to the supplying center.

Note: Centers may only operate with TİTCK-approved products, methods, and categories.

How do licensing and pre-approval processes work?

• Pre-approval: File to provincial health authority with project, staff, funding, and requested license type. Must convert to full license within 1 year.

• Full license application: Requires staff list, qualifications, SOPs, quality manual, equipment validation, IT security, insurance, service contracts, and GMP/GTP compliance.

• Inactive licenses: If no activity within 6 months, the license is revoked.

What are the quality, traceability, and data retention obligations?

• Quality Management System (QMS): SOPs, risk management, CAPA, internal audits, change control, recall systems.

• Infrastructure: controlled clean rooms, validated HVAC, contamination prevention.

• Equipment: annual calibration, IQ/OQ/PQ validations.

• Materials: supplier audits, critical consumables certification.

• Continuity: disaster recovery, backup equipment, tested annually.

• SEC (Single European Code): mandatory coding and labeling.

• Traceability: minimum 30 years of post-clinical application record retention.

• Retained samples: at least 2 years.

• QMS records: at least 10 years.

Critical: Products without SEC traceability cannot be distributed or applied clinically.

What about biobanking and ATMPs?

• Biobanks: Require TİTCK licensing, strong data protection, and access controls.

• ATMPs: A product is ATMP if it involves substantial manipulation, systemic effect, or non-homologous use.

• Unlicensed ATMPs cannot be transferred/applied outside clinical trials.

What prohibitions and sanctions apply?

• Unauthorized activity: immediate suspension and referral to prosecutors.

• Misleading advertising/hope marketing: strictly prohibited.

• Financial incentives for donors: forbidden (except necessary expenses).

• Commercialization of human tissues/cells: banned.

• Inspections: at least annually. Noncompliance = suspension/cancellation.

What do imports/exports and national reserves mean?

• National reserve: emergency stock for disasters.

• Import/export: only by licensed storage/distribution centers.

• National biovigilance system: monitors adverse reactions nationwide.

Who will be most affected?

What should you do before January 1, 2026?

First 30 days:

• Map current activities.

• Conduct gap analysis (SEC, records, validation, QMS).

• Appoint responsible persons (Medical, QMS, QC, Biovigilance, etc.).

Within 90 days:

• Draft SOPs.

• Set up SEC labeling.

• Validate critical equipment.

• Secure liability insurance.

Within 180 days:

• Conduct internal audit and CAPA cycle.

• Test business continuity.

• Audit suppliers.

By day 365:

• Submit complete licensing file.

• Finish staff training.

• Activate biovigilance reporting.

FAQs

Can donors receive payment?

No. Only reimbursement of necessary expenses.

Can unlicensed products be used?

No. Only within clinical trials.

How long must records be kept?

30 years post-application; 10 years for QMS docs; 2 years for retained samples.

Is SEC coding mandatory?

Yes. Products without SEC cannot be distributed or applied.

Is advertising allowed?

No. Misleading or promotional statements are banned.

Checklist for license applications

• Organizational chart & job descriptions

• Qualified responsible persons with credentials

• Quality manual, SOP list, SEC labels

• HVAC validation, clean room certification

• Critical consumables audit trail

• IT/data security documentation

• Liability insurance

• Supplier/third-party contracts

• Recall procedures

• Continuity/disaster recovery plan

• Staff training records

What are the penalties for non-compliance?

• Product recalls (with documentation kept 30 years).

• Destruction/quarantine of non-compliant products.

• Suspension/cancellation of activity licenses.

• Direct ministry intervention if recalls are mishandled.

Final word: Don’t underestimate the workload

• Pick your scope carefully (procurement vs processing vs storage).

• Build SEC and traceability systems early.

• Treat validation as integral, not paperwork.

• Keep a tight leash on third-party contracts—you remain liable.

• Avoid even the appearance of “hope marketing.”

CTA – Let’s close your compliance gap

If you’re running a hospital, biobank, or ATMP manufacturing line, you’ll need a premium compliance project: licensing strategy, GMP/GTP quality architecture, SEC labeling, validation, audits, and submission files.

Reach out for:

• 30-day gap analysis

• Licensing strategy & capacity planning

• QMS/SOP package & SEC system

• Validation master plan (IQ/OQ/PQ)

• Internal audit & CAPA cycle

• Licensing file preparation & inspection coaching

Contact us: We’ll pre-screen your current setup with a 15-point compliance checklist and provide a tailored proposal.

Would you like me to also prepare a condensed 1,200-word “executive briefing” version of this in English (for board-level presentations), or do you prefer to keep the full 3,000-word compliance blog format?